Andrew Galgoci

Statistics

Publications

Citations

2.5K

H-Index

Active since

2003

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Scynexis (United States)

Andrew Galgoci is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, enzyme inhibition, and pharmacology.

Publications per year

2003–2020

Publications

Platensimycin is a selective FabF inhibitor with potent antibiotic properties

Jun Wang, S.M. Soisson, Katherine Young et al. · Nature · 2006 · 815 citations

Pharmacy, Medicinal Chemistry, Pharmacology +9

Selective small-molecule inhibition of an RNA structural element

John A. Howe, Hao Wang, Thierry Fischmann et al. · Nature · 2015 · 417 citations

Life Sciences, Biochemistry, Molecular Biology +11

Discovery of platencin, a dual FabF and FabH inhibitor with <i>in vivo</i> antibiotic properties

Jun Wang, Srinivas Kodali, Sang Ho Lee et al. · Proceedings of the National Academy of Sciences · 2007 · 380 citations · Full text

Life Sciences, Microbiology, Pharmacology +14

Discovery of FabH/FabF Inhibitors from Natural Products

Katherine Young, Hiranthi Jayasuriya, John G. Ondeyka et al. · Antimicrobial Agents and Chemotherapy · 2006 · 200 citations · Full text

Life Sciences, Microbiology, Molecular Biology +14

Discovery of a Small Molecule That Inhibits Cell Division by Blocking FtsZ, a Novel Therapeutic Target of Antibiotics

Jun Wang, Andrew Galgoci, Srinivas Kodali et al. · Journal of Biological Chemistry · 2003 · 199 citations · Full text

Life Sciences, Microbiology, Molecular Biology +15

1–5 of 14